Core Insights - Climb Bio, Inc. is advancing two monoclonal antibodies, CLYM116 for IgA nephropathy and budoprutug for primary membranous nephropathy, with promising preclinical and clinical data to be presented at the 2025 ASN Kidney Week [1][2][3] Group 1: CLYM116 Development - CLYM116 is a novel anti-APRIL monoclonal antibody designed to treat IgA nephropathy, showing favorable pharmacokinetic and pharmacodynamic profiles in preclinical models [1][2] - The antibody promotes APRIL degradation and enhances antibody recycling, leading to significant reductions in IgA levels [2][9] - CLYM116 employs a pH-dependent binding mechanism, potentially allowing for less frequent dosing and a favorable safety profile [9] Group 2: Budoprutug Clinical Data - Budoprutug is an anti-CD19 monoclonal antibody targeting B-cell mediated diseases, with long-term follow-up data from a Phase 1b trial indicating sustained control of proteinuria for up to three years in patients with primary membranous nephropathy [3][7] - In the trial, four patients received up to four doses of budoprutug, with three patients not requiring further immunosuppressive treatment [3] - No significant treatment-related adverse events were reported, supporting further investigation of budoprutug as a potential disease-modifying therapy [3][8] Group 3: Presentation Details - Climb Bio will present CLYM116 data at ASN Kidney Week on November 8, 2025, with a poster titled "Development and Characterization of CLYM116" [5] - The abstract for budoprutug's long-term remission data in primary membranous nephropathy is also available, highlighting its clinical significance [5][4]
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025